Based on current technical patterns, ABCL stock forecast 2025 could see resistance near the $10–$12 range. Monthly moving average trends from late 2024 show a tightening channel, hinting at a possible breakout if pipeline success continues in oncology collaborations. While AbCellera Biologics seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). The consensus EPS estimate for the quarter has been revised 4.17% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investor risk analysis for ABCL stock forecast 2025 points out high dependency on milestone payments from partners. These payments, if met consistently, could strengthen 2025 earnings surprises and drive short-term spikes.